• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pfizer - Articles and news items


EU approval for Pfizer’s non-small cell lung cancer drug

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The drug exhibited marked anti-tumour activity in patients with ROS1-positive advanced NSCLC and met its primary endpoint of ORR. Tumours were tested for ROS1 rearrangements by laboratory-developed break-apart fluorescence in situ hybridization (FISH) (96%) or real-time polymerase chain reaction (RT-PCR) (4%) assay…

cancer drugs

Re-evaluating the Cancer Drugs Fund: Out with the old, in with the new

Blog, Z Homepage promo / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

In April of this year, NICE started to assess the cost and clinical effectiveness of every drug currently in the old cancer drugs fund…

anti-infective drug pfizer

Pfizer to acquire AstraZeneca’s anti-infective business

Industry news / 24 August 2016 / Pfizer

The agreement includes the rights to the newly approved EU drug zavicefta (ceftazidime-avibactam), the marketed agents merrem/meronem (meropenem) and zinforo (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL…

Crizotinib lung cancer price drop

NICE recommends Pfizer’s lung cancer drug after price drop

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value for money on the NHS…

global hiv treatment

Global dual-drug trial aims to advance HIV treatment

Industry news / 16 August 2016 / ViiV Healthcare

ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had no prior antiretroviral therapy…

pfizer vyndaqel rare disease

Pfizer’s Vyndaqel a success for rare disease

Industry news / 8 August 2016 / Pfizer

Treatement over varying periods of up to 5.5 years, showed that early stage treatment with Vyndaqel resulted in minimal neurological disease progression, and in preservation of body weight, which often declines as the disease progresses…

prevnar 13

FDA approves label expansion for Pfizer’s Prevnar 13

Industry news / 13 July 2016 / Victoria White, Digital Content Producer

Prevnar 13 is now approved for adults 18 years of age and older for the prevention of pneumococcal pneumonia and invasive disease caused by S. pneumoniae…


SMC accepts five new medicines for use in NHS Scotland

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib…


Positive trial results for Sutent as adjuvant therapy in RCC

Industry news / 8 July 2016 / Victoria White, Digital Content Producer

The S-TRAC study of Sutent versus placebo in the adjuvant setting met its primary endpoint of improving disease-free survival in renal cell carcinoma…


NICE says ‘yes ‘ to bosutinib for chronic myeloid leukaemia

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

Bosutinib is the first drug to go through the reappraisal process, where NICE assesses the cost and clinical effectiveness of drugs currently in the old CDF…

ovarian cancer

Phase III trial to evaluate avelumab as first-line treatment in ovarian cancer

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

Avelumab will be evaluated in combination with, and/or as follow-on treatment to, platinum-based chemotherapy in patients with epithelial ovarian cancer…


SPIRE-HR and SPIRE-FH trials of bococizumab meet primary endpoints

Industry news / 28 June 2016 / Victoria White, Digital Content Producer

Two Phase III trials of Pfizer’s bococizumab, SPIRE-HR (HighRisk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint…


Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +